Buy Like Buffett
Watchlist

Flagship explainer

How NIAGEN BIOSCIENCE, INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$129M · 100%Cost of revenue$46.2M · 36%Gross profit$83.2M · 64%Operating income$16.3M · 13%Income before tax$18.2M · 14%Income tax$810000 · 1%Net income$17.4M · 13%As of 2025-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$129M100%
  • 10-K · FY 2025Filing detailsAccession 0001386570-26-000013 · filed Mar 4, 2026
Cost of revenue$46.2M36%
  • 10-K · FY 2025Filing detailsAccession 0001386570-26-000013 · filed Mar 4, 2026
$83.2M64%
  • 10-K · FY 2025Filing detailsAccession 0001386570-26-000013 · filed Mar 4, 2026
$16.3M13%
  • 10-K · FY 2025Filing detailsAccession 0001386570-26-000013 · filed Mar 4, 2026
Income before tax$18.2M14%
  • 10-K · FY 2025Filing detailsAccession 0001386570-26-000013 · filed Mar 4, 2026
Income tax$8100001%
  • 10-K · FY 2025Filing detailsAccession 0001386570-26-000013 · filed Mar 4, 2026
$17.4M13%
  • 10-K · FY 2025Filing detailsAccession 0001386570-26-000013 · filed Mar 4, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001386570-26-000013 · filed Mar 4, 2026
· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full NIAGEN BIOSCIENCE, INC. analysis at Buy Like Buffett